These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11402621)

  • 1. Expression of the SART3 antigens in oral cancers.
    Fukuda K
    Kurume Med J; 2001; 48(1):55-8. PubMed ID: 11402621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the SART3 tumor rejection antigen in renal cell carcinoma.
    Kawagoe N; Shintaku I; Yutani S; Etoh H; Matuoka K; Noda S; Itoh K
    J Urol; 2000 Dec; 164(6):2090-5. PubMed ID: 11061933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides.
    Murayama K; Kobayashi T; Imaizumi T; Matsunaga K; Kuramoto T; Shigemori M; Shichijo S; Itoh K
    J Immunother; 2000; 23(5):511-8. PubMed ID: 11001544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of SART3 tumor-rejection antigen in gastric cancers.
    Niiya F; Nishizaka S; Matsunaga K; Koufuji K; Mori M; Katai H; Yamana H; Itoh K
    Jpn J Cancer Res; 2000 Mar; 91(3):337-42. PubMed ID: 10760694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients.
    Suefuji Y; Sasatomi T; Shichijo S; Nakagawa S; Deguchi H; Koga T; Kameyama T; Itoh K
    Br J Cancer; 2001 Apr; 84(7):915-9. PubMed ID: 11286471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of tumor-rejection antigens in gynecologic cancers.
    Tanaka S; Tsuda N; Kawano K; Sakamoto M; Nishida T; Hashimoto T; Shichijo S; Kamura T; Itoh K
    Jpn J Cancer Res; 2000 Nov; 91(11):1177-84. PubMed ID: 11092984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma.
    Komohara Y; Harada M; Arima Y; Suekane S; Noguchi M; Yamada A; Itoh K; Matsuoka K
    Int J Oncol; 2006 Dec; 29(6):1555-60. PubMed ID: 17088996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides.
    Tsuda N; Murayama K; Ishida H; Matsunaga K; Komiya S; Itoh K; Yamada A
    J Orthop Res; 2001 May; 19(3):346-51. PubMed ID: 11398844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes.
    Ito M; Shichijo S; Miyagi Y; Kobayashi T; Tsuda N; Yamada A; Saito N; Itoh K
    Int J Cancer; 2000 Nov; 88(4):633-9. PubMed ID: 11058882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of tumor rejection antigens in colorectal carcinomas.
    Sasatomi T; Suefuji Y; Matsunaga K; Yamana H; Miyagi Y; Araki Y; Ogata Y; Itoh K; Shirouzu K
    Cancer; 2002 Mar; 94(6):1636-41. PubMed ID: 11920522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes.
    Yamada A; Kawano K; Koga M; Matsumoto T; Itoh K
    Cancer Res; 2001 Sep; 61(17):6459-66. PubMed ID: 11522641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of immunogenic MAGED4B peptides for vaccine development in oral cancer immunotherapy.
    Lim KP; Chun NA; Gan CP; Teo SH; Rahman ZA; Abraham MT; Zain RB; Ponniah S; Cheong SC
    Hum Vaccin Immunother; 2014; 10(11):3214-23. PubMed ID: 25483651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell receptor Vbeta gene usage by T cells reactive with the tumor-rejection antigen SART-1 in oral squamous cell carcinoma.
    Kumamaru W; Nakamura S; Kadena T; Yamada A; Kawamura E; Sasaki M; Ohyama Y; Toyoshima T; Hayashida JN; Itoh K; Shirasuna K
    Int J Cancer; 2004 Feb; 108(5):686-95. PubMed ID: 14696095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonal diversity of cytotoxic T lymphocytes that recognize autologous oral squamous cell carcinoma.
    Kobayashi J; Hirohashi Y; Torigoe T; Michifuri Y; Yamamoto T; Tamura Y; Kamiguchi K; Miyazaki A; Yamaguchi A; Hariu H; Hiratsuka H; Sato N
    Hum Immunol; 2009 Feb; 70(2):89-95. PubMed ID: 19124056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles.
    Mohamed ER; Naito M; Terasaki Y; Niu Y; Gohara S; Komatsu N; Shichijo S; Itoh K; Noguchi M
    Int J Oncol; 2009 Feb; 34(2):529-36. PubMed ID: 19148489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the tumor-rejection antigen SART1 in brain tumors.
    Imaizumi T; Kuramoto T; Matsunaga K; Shichijo S; Yutani S; Shigemori M; Oizumi K; Itoh K
    Int J Cancer; 1999 Dec; 83(6):760-4. PubMed ID: 10597192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the SART1 tumor-rejection antigen in human osteosarcomas.
    Ishida H; Komiya S; Inoue Y; Yutani S; Inoue A; Itoh K
    Int J Oncol; 2000 Jul; 17(1):29-32. PubMed ID: 10853014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail.
    Akiyama Y; Maruyama K; Nara N; Mochizuki T; Yamamoto A; Yamazaki N; Kawashima I; Nukaya I; Takesako K; Yamaguchi K
    Anticancer Res; 2004; 24(2B):571-7. PubMed ID: 15160996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides.
    Miyagi Y; Imai N; Sasatomi T; Yamada A; Mine T; Katagiri K; Nakagawa M; Muto A; Okouchi S; Isomoto H; Shirouzu K; Yamana H; Itoh K
    Clin Cancer Res; 2001 Dec; 7(12):3950-62. PubMed ID: 11751487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.